Abstract
Retinal vein occlusions (RVOs) cause substantial vision loss and visual impairment in the working-age population, and disease burden is growing with an estimated 28.06 million people affected worldwide in 2015.1 Restoring and maintaining vision for RVO typically is reliant on frequent costly treatments and close surveillance, with anti–vascular endothelial growth factor (VEGF) agents often used as first-line treatments for the sequelae of RVO including macular edema and neovascularization. This large treatment and surveillance burden coupled with the cost of treatment options motivates cost-effectiveness analyses such as that performed by Kymes et al2 evaluating repackaged (compounded) bevacizumab compared with aflibercept for the treatment of macular edema associated with central RVO (CRVO) or hemiretinal RVO (HRVO).